缩写名/全名 |
DIABETES OBES METAB
DIABETES OBESITY & METABOLISM |
||||||||||||||||||||||||
ISSN号 | 1462-8902 | ||||||||||||||||||||||||
研究方向 | 医学-内分泌学与代谢 | ||||||||||||||||||||||||
影响因子 | 2015:6.198, 2016:6.715, 2017:5.98, 2018:6.133, 2019:5.9, | ||||||||||||||||||||||||
出版国家 | ENGLAND | ||||||||||||||||||||||||
出版周期 | Monthly | ||||||||||||||||||||||||
年文章数 | 323 | ||||||||||||||||||||||||
出版年份 | 1999 | ||||||||||||||||||||||||
是否OA | No | ||||||||||||||||||||||||
审稿周期(仅供参考) | 一般,3-8周 |
||||||||||||||||||||||||
录用比例 | 较易 | ||||||||||||||||||||||||
投稿链接 | http://mc.manuscriptcentral.com/dom | ||||||||||||||||||||||||
投稿官网 | http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1463-1326 | ||||||||||||||||||||||||
h-index | 112 | ||||||||||||||||||||||||
CiteScore |
|
||||||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1462-8902%5BISSN%5D | ||||||||||||||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | Risk of heart failure in a population with type 2 diabetes versus a population without diabetes with and without coronary heart disease. Author: Chen HF1,2, Ho CA3, Li CY4,5. Journal: Diabetes Obes Metab. 2019 Jan;21(1):112-119. doi: 10.1111/dom.13493. Epub 2018 Sep 4. PubMed DOI |
2. | Efficacy and safety of once-weekly dulaglutide versus insulin glargine in mainly Asian patients with type 2 diabetes mellitus on metformin and/or a sulphonylurea: A 52-week open-label, randomized phase III trial. Author: Wang W1, Nevárez L2, Filippova E3, Song KH4, Tao B1, Gu L5, Wang F5, Li P5, Yang J5. Journal: Diabetes Obes Metab. 2019 Feb;21(2):234-243. doi: 10.1111/dom.13506. Epub 2018 Oct 7. PubMed DOI |
3. | Efficacy and safety of sitagliptin added to treatment of patients with type 2 diabetes inadequately controlled with premixed insulin. Author: Yu M1, Shankar RR2, Zhang R3, Zhang Y3, Lin J2, O'Neill EA2, Chen G3, Liu S4, Tu Y4, Engel SS2. Journal: Diabetes Obes Metab. 2019 Feb;21(2):408-411. doi: 10.1111/dom.13517. Epub 2018 Oct 3. PubMed DOI |
4. | FGF21 decreases food intake and body weight in obese Göttingen minipigs. Author: Christoffersen B1, Straarup EM1, Lykkegaard K1, Fels JJ1, Sass-Ørum K1, Zhang X2, Raun K1, Andersen B. Journal: Diabetes Obes Metab. 2019 Mar;21(3):592-600. doi: 10.1111/dom.13560. Epub 2018 Nov 20. PubMed DOI |
5. | Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes. Author: Borg MJ1, Bound M1, Grivell J1, Sun Z2, Jones KL1,3, Horowitz M1,3, Rayner CK1, Wu T1,2,3. Journal: Diabetes Obes Metab. 2019 Mar;21(3):640-647. doi: 10.1111/dom.13567. Epub 2018 Nov 21. PubMed DOI |
6. | Dynamic changes in insulin and glucagon during disease progression in rhesus monkeys with obesity-related type 2 diabetes mellitus. Author: Wang C1,2, Xiao Y1,2, Wang J1,2, Hou N1,2, Cui W1,2, Hu X1,2, Zeng F1,2, Yuan Y1,2, Ma D1,2, Sun X1,2, Zhang Y1,2,3, Zheng W1,2, Liu Y1,2, Shang H1,2, Chen L1, Xiao RP1,2,3, Zhang X1,2. Journal: Diabetes Obes Metab. 2019 May;21(5):1111-1120. doi: 10.1111/dom.13624. Epub 2019 Jan 22. PubMed DOI |
7. | Metformin attenuates the postprandial fall in blood pressure in type 2 diabetes. Author: Borg MJ1, Jones KL1,2, Sun Z3, Horowitz M1,2, Rayner CK1, Wu T1,2,3. Journal: Diabetes Obes Metab. 2019 May;21(5):1251-1254. doi: 10.1111/dom.13632. Epub 2019 Jan 30. PubMed DOI |
8. | Dimorphic autoantigenic and protective effects of Reg2 peptide in the treatment of diabetic β-cell loss. Author: Yu L1,2, Li X1, Zhang Z1, Du P1, Liu JL2, Li Y1, Yin T1, Yu W1, Sun H1, Wang M1,3, Luo C1. Journal: Diabetes Obes Metab. 2019 May;21(5):1209-1222. doi: 10.1111/dom.13644. Epub 2019 Mar 1. PubMed DOI |
9. | Direct medical costs in the preceding, event and subsequent years of a first severe hypoglycaemia episode requiring hospitalization: A population-based cohort study. Author: Wong CKH1, Tong T2, Cheng GHL1, Tang EHM1, Thokala P2, Tse ETY1, Lam CLK1. Journal: Diabetes Obes Metab. 2019 Jun;21(6):1330-1339. doi: 10.1111/dom.13657. Epub 2019 Mar 19. PubMed DOI |
10. | Randomised study of evolocumab in patients with type 2 diabetes and dyslipidaemia on background statin: Primary results of the BERSON clinical trial. Author: Lorenzatti AJ1, Eliaschewitz FG2, Chen Y3, Lu J4, Baass A5, Monsalvo ML6, Wang N6, Hamer AW6, Ge J7. Journal: Diabetes Obes Metab. 2019 Jun;21(6):1455-1463. doi: 10.1111/dom.13680. Epub 2019 Apr 2. PubMed DOI |
|
|